EMA Authorised: Baraclude (Entecavir) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Baraclude (entecavir) for chronic hepatitis B. The marketing authorization holder is Bristol-Myers Squibb Pharma EEIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Baraclude (entecavir)

Snippet

Status: Authorised. Therapeutic area: Hepatitis B, Chronic. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 03/12/2025